NRX Therapeutics: Pioneering Covid‑19, Respiratory & Mental Health Treatments Amid Growing Market Momentum
NRX Therapeutics, a clinical‑stage pharma company, is advancing investigational drugs for COVID‑19, respiratory diseases, depression and PTSD, with a Nasdaq‑listed stock at $1.84 and a $54.5M market cap, aiming to bring life‑changing therapies world…
2 minutes to read